ProNAi Therapeutics, Inc. to Post FY2017 Earnings of ($0.84) Per Share, SunTrust Banks Forecasts (SRRA)

ProNAi Therapeutics, Inc. (NASDAQ:SRRA) – Stock analysts at SunTrust Banks increased their FY2017 earnings per share (EPS) estimates for ProNAi Therapeutics in a note issued to investors on Thursday. SunTrust Banks analyst Y. Suneja now forecasts that the biotechnology company will post earnings of ($0.84) per share for the year, up from their prior forecast of ($0.92). SunTrust Banks also issued estimates for ProNAi Therapeutics’ Q4 2017 earnings at ($0.20) EPS, Q1 2018 earnings at ($0.21) EPS, Q2 2018 earnings at ($0.22) EPS, Q3 2018 earnings at ($0.23) EPS, Q4 2018 earnings at ($0.19) EPS, FY2018 earnings at ($0.86) EPS, FY2020 earnings at ($1.00) EPS and FY2021 earnings at ($1.00) EPS.

ProNAi Therapeutics (NASDAQ:SRRA) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.03.

WARNING: “ProNAi Therapeutics, Inc. to Post FY2017 Earnings of ($0.84) Per Share, SunTrust Banks Forecasts (SRRA)” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at

A number of other equities research analysts have also issued reports on SRRA. Jefferies Group LLC restated a “hold” rating on shares of ProNAi Therapeutics in a report on Thursday, July 27th. ValuEngine upgraded shares of ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research lowered shares of ProNAi Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. ProNAi Therapeutics currently has an average rating of “Hold” and an average price target of $4.00.

Shares of ProNAi Therapeutics (NASDAQ SRRA) opened at $1.92 on Monday. ProNAi Therapeutics has a 1-year low of $1.10 and a 1-year high of $2.25.

A hedge fund recently bought a new stake in ProNAi Therapeutics stock. FMR LLC acquired a new stake in ProNAi Therapeutics, Inc. (NASDAQ:SRRA) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 197,100 shares of the biotechnology company’s stock, valued at approximately $302,000. FMR LLC owned 0.38% of ProNAi Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 55.65% of the company’s stock.

About ProNAi Therapeutics

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Earnings History and Estimates for ProNAi Therapeutics (NASDAQ:SRRA)

Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply